<DOC>
	<DOCNO>NCT01743053</DOCNO>
	<brief_summary>This prospective , randomise , open label , control pilot study evaluate safety preliminary effectiveness ReCell Autologous Cell Harvesting Device ( ReCell ) management chronic leg ulcer associate venous insufficiency . Outcome compare study participant receive standard care ( debridement , compression therapy ) participant receive ReCell addition standard care .</brief_summary>
	<brief_title>A Pilot Trial Use ReCell® Autologous Cell Harvesting Device Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>1 . Chronic venous leg ulcer ( CEAP Clinical classification 6 ) 1 . Confirmed , actively manage venous reflux 2 . No exposed tendon bone 3 . Ulcer &gt; 4 week duration 4 . Ulcer surface area 2cm2 80cm2 2 . ABI ≥ 0.8 3 . The patient 18 year age old 4 . The patient willing complete followup evaluation require study protocol 5 . The patient able abstain treatment ulcer duration study , unless medically necessary 6 . The patient agree abstain enrolment clinical trial duration study 7 . The patient able read understand instruction give voluntary write informed consent 8 . The patient able willing follow protocol requirement ( include compression therapy ) 9 . Patients enrol site France must affiliation social security scheme 1 . Study treatment area expose bone tendon 2 . Poorly control diabetes 3 . Arterial insufficiency ( ABI &lt; 0.8 ) 4 . Pregnant/lactating female ( selfreported test , per institutional requirement ) 5 . The patient active wound infection require antibiotic therapy 6 . The patient prior surgical treatment ulcer within past 60 day 7 . The patient life expectancy 1year less 8 . The patient severe dermatological disorder ( e.g . severe psoriasis , epidermolysis bullosa , pyoderma gangrenosum ) . 9 . The patient unable follow protocol 10 . The patient taking , take past 60 day , mycophenolate mofetil &gt; 10mg corticosteroid per day . 11 . The patient concurrent condition opinion investigator may compromise patient safety study objectives 12 . The patient know hypersensitivity trypsin Compound Sodium Lactate Irrigation ( Hartmann 's ) solution . 13 . The patient vulnerable protect adult . 14 . The patient unable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>